Macrophage homeostasis implies proper function for its specific tissue, environment and challenge

Reprogramming imbalanced macrophage populations can lead to disease resolution
Macrophages’ function is a sum of their designation, the local environment in which they reside, and the type of situation or pathogen to which they are exposed. Reprogrammed out of their homeostatic state, macrophages contribute to the pathophysiology of multiple diseases including cancer and various inflammatory disorders.

Allocetra™ immune rebalancing

Allocetra™ is an innovative immunotherapy that is being developed to reprogram macrophages,
which were negatively reprogrammed by certain diseases out of their homeostatic state.

We reset macrophages into their homeostatic state

Non-homeostatic macrophages
Allocetra™ infusion
Macrophage feeding
Macrophages reset
Homeostasis restored

Pipeline of reprogrammable macrophage-modulated indications

  Indication Global
Market Size
Potential support for EU Conditional
Marketing Approval
Post EU
US Phase 3
Organ failure associated with Sepsis $33B   Completed Randomized,
Phase II ongoing
Top-line data for Phase II April 24’
Moderate knee osteoarthritis $7B     Randomized,
controlled Phase I/II
expected Q1 2024
Top-line data for Phase I/II Q3-25’
End-stage knee osteoarthritis $2B   Phase I/II
  Top-line data for Phase I/II EOQ3-24’

Our Mission

Our mission is to establish new equilibriums that solve complex diseases.

As a clinical-stage company focused on macrophage reprogramming, we intend to develop and commercialize a drug pipeline for macrophage reprogramming in Sepsis, Osteoarthritis, solid cancers, COVID-19 and other indications.

Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach.

Strong leadership,
inspired by great science and a sense of mission

Our management, clinical advisors, personnel, and affiliates have extensive knowledge in the research and development of therapies based on macrophage reprogramming.

Find out more

14 Einstein St. Nes-Ziona 7403618, Israel
T +972.8.6380330